Floatz logo

Inno-206

CD20 Positive

M.D. Anderson Cancer CenterPhase 2Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the CD20 Positive cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 2BB
Cyclophosphamide
Jonsson Comprehensive Cancer Center
Phase 2BB
METHOTREXATE
M.D. Anderson Cancer Center
Phase 2BB
DEXAMETHASONE
M.D. Anderson Cancer Center
Phase 2BB
PREDNISONE TABLETS
M.D. Anderson Cancer Center
Phase 2BB

View all 30 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →